Creators of Muscle Milk release hemp-infused fitness beverage

Source: HempIndustryDaily.com | Author: Hemp Industry Daily | Jun 30, 2022

The creators of Muscle Milk, a popular protein drink, on Wednesday released a new energy drink infused with hemp.

According to a news release, Gym Weed, made by Alternative Biologics, does not contain THC.

Instead, the pre-workout beverage contains 20 milligrams of hemp extract and 200 milligrams of caffeine as well as other natural supplements.

The release did not say if the hemp extract contains cannabinoids such as CBD. The makers of Gym Weed formulated the recipe for Muscle Milk but do not produce it. Muscle Milk is owned by PepsiCo, which bought the protein drink company in 2019 for $465 million, according to Food Business News. The release marks another instance of retail products containing hemp that target the fitness-supplement market.

He’s Now Cancer Free After Stage 4 Pancreatic Cancer

Source: CannabisHealthRadio.com | Author: Cannabis Health Radio | Jun 28, 2022

After being diagnosed with pancreatic cancer in the Fall of 2021, Bob and his wife Tami from the U.S. decided to do everything they could to make him well again. Bob underwent 12 rounds of chemotherapy but he also started taking cannabis oil by suppository, working up to a gram a day. Additionally, he changed his diet and started taking supplements. Bob’s doctor “didn’t know how to explain it” when he got the all clear several weeks ago. No sign of cancer. This is an emotional, good news story that’s worth the time to listen.

Cannabis-based colon cancer treatment kill 90% of deadly cells

A new study performed by Cannabotech has demonstrated that the company’s range of Integrative-Colon products may be an effective colon cancer treatment, killing 90% of colon cancer cells in a cell model study.

Source: HealthEuropa.eu | Author: HealthEuropa | Mar 17, 2022

Cannabotech is a biotechnology company pioneering oncological products comprised of cannabis and mushroom extracts. In a recent cell model study, the company has demonstrated that its Integrative-Colon products, which are based on an array of cannabinoids from the cannabis plant and various mushroom extracts, eliminated over 90% of colon cancer cells. The findings offer an exciting prospect for the future of colon cancer treatment.

How did the Integrative Colon products perform?

For their study, the researchers analysed the effectiveness of the Integrative Colon products on a range of colon cancer subtypes, representing different molecular changes that a prevalent in these cancer subtypes. The team compared the composition of the products with the activity of each cannabinoid individually.

The results suggested that the composition of the Integrative Colon products was more effective than each cannabinoid individually, highlighting a strong synergy between the active ingredients. These findings back up claims from Cannabotech that to achieve an effective cannabis colon cancer treatment, it is essential to amalgamate a defined, accurate, and science-based formula that cannot be achieved in any cannabis strain that exists in nature.

Additionally, the study showed the different effects of each cannabinoid on distinct colon cancer subtypes. This echoes the essential need for a individualised approach for patients’ health needs, such as the personalised technology already developed by Cannabotech that will soon hit the market in the UK, US, and Israel at the end of 2022.

The mushroom extracts in the products contain an enriched and high concentration of an active substance called PSK that is extracted from the Trametes mushroom. PSK is known for its anti-cancer properties and has been approved as an oncology treatment in Taiwan, Japan, and South Korea.

Future steps

The researchers are now looking to assess the effectiveness of the formula in combination with standard chemotherapies. In addition, the team plan to combine the cannabinoid formula with the mushroom Cyathus Striatus as part of the botanical drug development project.

Elhanan Shaked, the CEO of Cannabotech, commented: “This is a significant milestone in Cannabotech’s growth to becoming a leader in integrative oncology medicine. The integrative products developed by Cannabotech are intended for use in combination with chemotherapy treatment to reduce its side effects. Cannabotech’s solutions will be launched in Israel and the US towards the second half of 2022, while the company’s goal is to define a new standard for the medical cannabis industry.”

Professor Tami Peretz, Senior Oncologist, said: “Colon cancer is one of the most common tumours today, with a significant proportion of patients currently treated with integrative therapies, in combination with traditional methods, including the administration of medical cannabis. Cannabotech’s Integrative products are unique in that they are designed to standards similar to those of the pharmaceutical industry and incorporate many active ingredients. The company’s products have demonstrated impressive and very promising efficacy in colon culture cells tested in the laboratory. Based on these experiments, there is room to perform animal studies and, in the future, to examine the possibility of incorporating these products in colorectal cancer patients.”

Isaac Angel, Cannabotech’s pharmacological consultant, said: “The significant synergistic effect demonstrated by the combination of active ingredients eliminated over 90% of all types of cancer cells used in the study. Furthermore, this was achieved without the presence of THC, which is the cannabinoid substance producing the “high” effect, whereas each of the other cannabinoids tested individually demonstrated different effects on the various cell types. We are encouraged by these results, which constitute another important milestone in proving the scientific feasibility of the products and highlight the need for medical care customisation. We shall continue to work to provide a cure for patients.”

Olivia Newton-John Relies On Her Husband’s Homegrown Cannabis For Relieving Cancer Symptoms

The Grease actress says cannabis is a “healing plant” and wants nothing more than Aussies to gain legal access to plant-based medicine.

Source: Herb.co | Author: BuzzMusic | Mar 15, 2022

In 1992, actress and singer Olivia Newton-John was first diagnosed with breast cancer but didn’t see any signs of it letting up until entering remission in 2013. Now, reports say the star is under the weight of cancer once again, this time spreading to her spine. 

Aside from the unfortunate diagnosis and state of her health, Newton-John focuses on the “positive side of things, no matter what the challenge,” she told The Daily Mail while also citing that cannabis has played a major role in her everyday life. 

She first started considering cannabis use when her husband, John Easterling, began cultivating many different strains on their farm in California. A Good Housekeeping article mentioned how Easterling began his ventures in plant-based medicine in the 90s after founding herbal wellness business Amazon Herb Company.

Photo by Kathryn Burke / Pexels

Fast forward to today, Easterling is proud to be growing a handful of different strains, 21 to be exact, that were all specifically designed to combat chronic pain, nausea, and inflammation for Newton-John. 

And so far, she’s loved every one of them. In 2020, the Grease actress sat down for an interview with Andy Cohen on Watch What Happens Live, where she explained how cannabis has truly helped her with “pain, with sleep, with anxiety, I believe with inflammation,” reports Prevention. 

Prevention also wrote that Newton-John’s positive experience with cannabis resulted in her urging the Australian government to legalize medical marijuana. She added that it’s a “healing plant” and “is something that should be available to everyone who is going through a chronic illness or pain.”

Her admiration for medical marijuana has extended into ventures with her Olivia Newton-John Foundation Fund: Beyond Cancer, which sheds like on the many benefits of plant-based medicine, not to mention her hospital in Australia, the Olivia Newton-John Cancer Wellness, and Research Center.

Study: History of Marijuana Use Not Associated with Increased Heart Attack Risk

Source: Norml.org | Author: Norml | Feb 17, 2022

New York, NY: Cannabis smoke exposure is not positively associated with an increased risk of myocardial infarction, according to data published in the journal Cureus

A pair of researchers with the Icahn School of Medicine at Mount Sinai in New York City assessed the association between a history of cannabis smoking and heart attack in a cohort of over 500,000 subjects from the United Kingdom.

Researchers identified an inverse association between cannabis use and incidences of myocardial infarction, and they found no correlation between marijuana consumption and heart attack severity. 

“With marijuana use, MI [myocardial infarction] decreased,” authors concluded. They further acknowledged: “The association of marijuana use with reduced risk of MI is not entirely in accord with current assumptions about the cardiac effects of marijuana. … Further studies are warranted.”

Studies assessing the association between cannabis use and cardiovascular health have been inconsistent, with some studies finding an increased risk of stroke and other cardiovascular diseases among marijuana consumers while others report either no risk or provide evidence of possible cardioprotection

Full text of the study, “Marijuana and myocardial infarction in the UK Biobank cohort,” appears in Cureus.

Apple Secretly Joined Amazon In Advancing Commercial Cannabis Reform

Source: Forbes.com | Author: Robert Hoban | Feb 15, 2022

This past summer, a little recognized thing occurred — one of the largest and most respected companies in the world quietly changed its policies in favor of cannabis. That company was Apple. As a result, they joined the ranks of Amazon as a global corporation advocating for policy reform that would open a federally legal, commercial cannabis industry in the United States.

For years, large tech companies, including Facebook and Google, have refused to acknowledge the legality of industrial hemp, let alone the legality of medical or recreational marijuana. Finally, Apple bucked that trend. In June, the fine print of Apple’s “App Store Review Guidelines” release stated that apps handling sales and delivery of medical and recreational cannabis in legal jurisdictions are now allowed on the App Store. This was monumental.  

Unlike the big headlines we’ve seen recently from Amazon, Uber, the NFL, and other mainstream, institutional businesses, showing a positively changing attitude toward cannabis, Apple made no big-splash announcement that this had happened. Yet, this change came at a time of a shift in the cannabis paradigm for voters, policymakers, and the average American. 

As we’ve discussed previously, U.S. voters are shifting rapidly and dramatically in favor of cannabis legalization. The most recent Gallup poll showed that 68% of American voters support some form of legalization. There’s also tremendous momentum from the recent unveiling of the Cannabis Administration and Opportunity Act by Senate Majority Leader Chuck Schumer (D-NY), Senate Finance Committee Chairman Ron Wyden (D-OR) and Sen. Cory Booker (D-NJ).

The financial technology experts at ArtisIQ are ahead of the curve in identifying the imperative to collaborate with tech leaders like Apple to update policy to reflect the mainstream adoption of cannabis. Co-Founder and CMO of Artis, Adair Lion shares, “As a fintech company on the cutting-edge of development in both cannabis and retail, Apple’s Policy changes are a monumental shift in the way our society does mobile transactions.”

When political leaders and Fortune 100 companies begin modifying policies and behavior to accommodate something that has been seen as fringe, elicit, or otherwise illegal, the hearts and minds of American start to change. It’s safe to say the tide is turning. 

This is the kind of influence that sets the tone for mainstream behavior. Think back to the early days of Babe Ruth and baseball, where ball players were smoking cigarettes in the dugout and cigarette advertisements abounded. Or more recently, Elon Musk and Tesla’s support of cryptocurrency which influenced much wider adoption and made the price of Bitcoin soar. 

The fine print of Apple’s policy update states that apps involved in the sale of cannabis are exclusive to licensed legal entities and strictly require geo-fencing within the legal jurisdiction. This requires an enormous amount of technological and regulatory compliance and is precisely where a fintech software company like Artis could excel. Consumer behavior shows the need for embedded digital payment technology. There’s been modest growth in payment and technology solutions for the cannabis industry and ancillary service providers. This is in no small part due to federal illegality and the fragmented nature of the industry.   

Apple’s policy adjustments are just an example of the level of innovation and attention to detail that Artis is providing to the cannabis industry. What is it that propels some tech companies above the rest? It’s those that provide solutions for the world’s most complex problems. It’s plain to see that cannabis has presented enormous complexity to politicians, enterprise businesses, and just about every other imaginable cog in the machine of our modern world.  

The contributions of experienced professionals are unequivocally what is necessary to propel cannabis further into the mainstream. These are the building blocks, the intimate details, that ultimately bring to reality the hopes of grand legislation, like the Cannabis Administration and Opportunity Act. Compliant and lawful participation in the cannabis ecosystem is paramount to widespread, mainstream adoption. As one who has had to navigate the grey areas of cannabis law for many years – and I’m as honest as a Denver man can be – I will always applaud the hard work to deliberately pave the way forward for this industry.

Another bill to raise U.S. THC limit to 1.0% introduced in Congress

Source: HempToday.com | Author: HempToday | Feb 8, 2022

A new bill introduced in the U.S. Congress would raise the limit for THC in hemp from 0.3% to 1.0% and adjust other provisions in current law to ease the path to market for producers.

The Hemp Advancement Act of 2022, introduced by Rep. Chellie Pingree, a Maine Democrat, addresses issues arising from the 2018 Farm Bill, which legalized industrial hemp federally.

In addition to raising the THC limit for crops in the field, provisions in the bill aimed at protecting consumers would set the combined limit for delta-9 and other forms of THC in hemp products at 0.3%.

Raising the limit to 1.0% THC in the field would protect farmers from their crops going hot, and protect producers from hemp going over that limit during the production process, which now makes them technically illegal.

Other key provisions

Other proposed provisions would provide additional protections for the processing and transportation of “hot” hemp, end a Drug Enforcement Agency monopoly on registering testing laboratories, and repeal a controversial ban on drug felons obtaining hemp licenses. 

Under current rules in the Farm Bill, hemp growers and processors often struggle to navigate THC testing and transportation requirements. Meanwhile, consumers are often confused by products that are marketed as hemp but which are more appropriately sold in recreational marijuana sales channels.

U.S. Sen. Rand Paul of Kentucky has twice introduced a separate measure, the Hemp Economic Mobilization Plan Act, which also includes a proposal to raise the THC limit to 1.0%. The U.S. National Association of State Departments of Agriculture has supported the change.

PepsiCo’s new US hemp drink aimed at younger, female customers

Source: HempIndustryDaily.com | Author: Hemp Industry Daily | Feb 2, 2022

PepsiCo has younger female consumers in mind with the U.S. launch of hempseed-infused energy drinks.

Rockstar Energy, a drinks brand owned by PepsiCo, says its three flavors of Rockstar Unplugged with hempseed are aimed at younger females who don’t gravitate toward energy drinks as commonly as males.

The drinks launched nationwide Tuesday and retail for $1.99 for a 12-ounce can, the company said. They contain no cannabinoids.

“Ninety-one percent of our consumers told us they wanted a beverage that lifts their mood,” said Fabiola Torres, PepsiCo general manager and chief marketing officer of its energy business.

PepsiCo released a line of hemp-infused energy drinks in Germany last year and was pleased with the results.

Last summer, PepsiCo joined its rival Coca-Cola and consumer product goods giants including Kellogg in appealing to U.S. health regulators to get going on regulations to allow over-the-counter CBD.

The letter from the Consumer Brands Association argued that current U.S. policy on CBD “is not working” because CBD is not allowed in foods, drinks and dietary supplements, but such products are nonetheless commonly sold by companies flouting regulations from the U.S. Food and Drug Administration.

PepsiCo planto promote its new hemp drink with a three-concert series in conjunction with MTV’s Unplugged franchise.

Florida ag commissioner backs marijuana legalization to clear way for hemp

Source: HempToday.net | Author: Hemp Today | Sept 2, 2021

A lack of clarity in federal cannabis laws is suppressing growth of the legal hemp industry, according to Florida Agriculture Commissioner Nikki Fried, who this week wrote a letter to U.S. Senate leaders backing cannabis reform legislation that would end the prohibition on marijuana.

In the letter, addressed to Senate Majority Leader Chuck Schumer (NY), Senator Ron Wyden (OR), and Senator Cory Booker (NJ), the bill’s sponsors, Fried also emphasized the need for the Food & Drug Administration (FDA) to classify hemp as a food ingredient.

Fried said the current arbitrary line defining when a product is deemed hemp and legal versus marijuana and illegal often means hemp farmers have problems with access to capital, federal research funding, insurance protections, disaster relief, federal trade promotion programs, and employment protections.

Conflicts

“While the burgeoning growth of the hemp industry is promising, it has also revealed the need for federal action to resolve the conflicts arising from the federal prohibition of marijuana,” Fried wrote in the letter, dated Aug. 31.

Fried’s recommendations address the Cannabis Administration and Opportunity Act, legislation proposed by the three senators which would end the federal marijuana ban while allowing states to determine their own cannabis laws.

“If left unresolved, these unnecessary hurdles could suppress the growth of the hemp industry that is projected to increase at 32 percent annually through 2027 as our nation moves toward more environmental and health-conscious products,” the commissioner wrote.

Federal inaction also means state-legal marijuana industries are stifled, Fried warned.

Focus on food

FDA classification of hemp as a food ingredient would also qualify its derivatives for inclusion in supplements, according to the Florida Department of Agriculture & Consumer Services (FDACS). If hemp, on the other hand, is first recognized as a supplement, it may not then cross over and be used as a food ingredient (despite the fact that supplement manufacturing standards are more stringent than those for making food).

Florida’s current legal and regulatory structures are “built on the understanding that hemp is a food additive,” FDACS noted in analysis Fried included with her letter to the senators.

Progress, challenges

Florida has approved more than 800 hemp cultivation permits for farmers in 65 of the state’s 67 counties since FDACS began accepting applications to grow industrial hemp early in 2020. Roughly 22,000 of 30,000 acres approved for planting were farmed last year, according to FDACS figures, representing at least a theoretical economic impact of roughly $300 million, with $136 million in revenue and more than 8,000 jobs created.

But researchers studying hemp’s potential in Florida say they haven’t yet found many hemp varieties viable in the state’s tropical and subtropical climates – a challenge faced by agronomy experts from Latin America to Africa to Southeast Asia, where countries are rushing to roll out hemp initiatives. Regions at tropical latitudes have struggled to find varieties that will flourish and still meet rules governing maximum amounts of THC.

Costs of prohibition

Florida’s hemp plan has been approved by the U.S. Department of Agriculture, but the state opted to remain under rules in the 2014 Farm Bill hemp pilot program for one more year after the USDA offered that option at the end of 2020. Hemp states without federally approved plans got the one-year extension to give regulators more time to harmonize local and federal laws.

Fried said marijuana legalization would also help resolve conflicts between federal and state laws governing medical and adult-use cannabis. The Cannabis Administration and Opportunity Act would expunge federal non-violent marijuana crimes, and reinvest federal cannabis tax revenue into communities historically afflicted by the “War on Drugs.”

“Continued marijuana criminalization demands billions in social, economic, and criminal justice costs, while forgoing billions in potential tax revenue,” Fried wrote in her letter to the Senators.

Clinical Study Reports No Evidence of Liver Toxicity in CBD

Source: Hemp Supporter | Author: Hemp Supporter | Mar 24, 2021

We’re excited to announce the results of an important clinical study conducted by ValidCare on CBD: Preliminary results reveal no evidence of liver toxicity.

Since passage of the 2018 Farm Bill, the FDA has been investigating a pathway to regulate the sale of ingestible hemp-derived CBD products. Unfortunately, the agency has not taken any concrete steps, claiming that it needs more real-world data on CBD’s safety profile.

As part of the hemp industry’s continuing effort to provide FDA data, ValidCare commissioned a study and concluded that “preliminary findings show no evidence of liver disease in the 839 participants and no increase in the prevalence of elevated liver function tests when compared to a population with a similar incidence of medical conditions.”

Major kudos to ValidCare, as well as to the US Hemp Roundtable members who funded and participated in the study: American Shaman, CBD Distillery, Charlotte’s Web, Hemp Fusion, Kannaway and Medterra.

Evidence like this confirms that it is high time for FDA to legally recognize and regulate ingestible hemp-derived CBD products. That’s why it’s so important that Congress pass HR 841, which would establish a legal pathway for the sale of hemp-derived extracts as dietary supplements.

Please use our online portal to email your U.S. Representative today, urging him or her to co-sponsor HR 841.